1
|
Jaito N, Phetlum S, Saeoung T, Tiyasakulchai T, Srimongkolpithak N, Uengwetwanit T. Improving stereoselectivity of phosphotriesterase (PTE) for kinetic resolution of chiral phosphates. Front Bioeng Biotechnol 2024; 12:1446566. [PMID: 39139291 PMCID: PMC11319162 DOI: 10.3389/fbioe.2024.1446566] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2024] [Accepted: 07/16/2024] [Indexed: 08/15/2024] Open
Abstract
Specific stereoisomer is paramount as it is vital for optimizing drug efficacy and safety. The quest for the isolation of desired stereoisomer of active pharmaceutical ingredients or key intermediates drives innovation in drug synthetic and biocatalytic methods. Chiral phosphoramidate is an important building block for the synthesis of antiviral drugs such as remdesivir and sofosbuvir. Given the clinical potency of the (Sp)-diastereomer of the drugs, an enzyme capable of completely hydrolyzing the (Rp)-diastereomer is needed to achieve the purified diastereomers via biocatalytic reaction. In this study, protein engineering of phosphotriesterase (PTE) was aimed to improve the specificity. Employing rational design and site-directed mutagenesis, we generated a small library comprising 24 variants for activity screening. Notably, W131M and I106A/W131M variants demonstrated successful preparation of pure (Sp)-diastereomer of remdesivir and sofosbuvir precursors within a remarkably short hydrolysis time (<20 min). Our work unveils a promising methodology for producing pure stereoisomeric compounds, utilizing novel biocatalysts to enable the chemoenzymatic synthesis of phosphoramidate nucleoside prodrugs.
Collapse
Affiliation(s)
| | | | | | | | | | - Tanaporn Uengwetwanit
- National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), Khlong Luang, Thailand
| |
Collapse
|
2
|
Li H, Lu C, Liu Z, Xiang F, Liu B, Wang H, Chang J, Pan L, Chen Y, Chen J. Advancements in bioscavenger mediated detoxification of organophosphorus poisoning. Toxicol Res (Camb) 2024; 13:tfae089. [PMID: 38863796 PMCID: PMC11163184 DOI: 10.1093/toxres/tfae089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2024] [Accepted: 06/04/2024] [Indexed: 06/13/2024] Open
Abstract
Background Organophosphorus compounds, widely used in agriculture and industry, pose a serious threat to human health due to their acute neurotoxicity. Although traditional interventions for organophosphate poisoning are effective, they often come with significant side effects. Objective This paper aims to evaluate the potential of enzymes within biological organisms as organophosphorus bioclearing agents. It analyses the technical challenges in current enzyme research, such as substrate specificity, stereoselectivity, and immunogenicity, while exploring recent advancements in the field. Methods A comprehensive review of literature related to detoxifying enzymes or proteins was conducted. Existing studies on organophosphorus bioclearing agents were summarised, elucidating the biological detoxification mechanisms, with a particular focus on advancements in protein engineering and novel delivery methods. Results Current bioclearing agents can be categorised into stoichiometric and catalytic bioclearing agents, both of which have shown some success in preventing organophosphate poisoning. Technological advancements have significantly improved various properties of bioclearing agents, yet challenges remain, particularly in substrate specificity, stereoselectivity, and immunogenicity. Future research will focus on expanding the substrate spectrum, enhancing catalytic efficiency, prolonging in vivo half-life, and developing convenient administration methods. Conclusion With the progression of clinical trials, bioclearing agents are expected to become widely used as a new generation of therapeutic organophosphate detoxifiers.
Collapse
Affiliation(s)
- Hexi Li
- Institute of NBC Defence, PLA, ARMY, 1 North Street, Yangfang Town, Changping District, Beijing 102205, China
- Unit No. 31666 of PLA, 1 New City Courtyard, Jinyang Town, Liangzhou District, Wuwei, Gansu 733000, China
| | - Cong Lu
- Institute of NBC Defence, PLA, ARMY, 1 North Street, Yangfang Town, Changping District, Beijing 102205, China
- Unit No. 94347 of PLA, 24 Wenfu Road, Shenhe District, Shenyang, Liaoning 110000, China
| | - Zhenmin Liu
- Institute of NBC Defence, PLA, ARMY, 1 North Street, Yangfang Town, Changping District, Beijing 102205, China
| | - Fengshun Xiang
- Institute of NBC Defence, PLA, ARMY, 1 North Street, Yangfang Town, Changping District, Beijing 102205, China
| | - Bo Liu
- Institute of NBC Defence, PLA, ARMY, 1 North Street, Yangfang Town, Changping District, Beijing 102205, China
| | - Hongjuan Wang
- Institute of NBC Defence, PLA, ARMY, 1 North Street, Yangfang Town, Changping District, Beijing 102205, China
| | - Jie Chang
- Institute of NBC Defence, PLA, ARMY, 1 North Street, Yangfang Town, Changping District, Beijing 102205, China
| | - Li Pan
- State Key Laboratory of NBC Protection for Civilians, 30 South Central Street, Yangfang Town, Changping District, Beijing 102205, P. R. China
| | - Youwei Chen
- Institute of NBC Defence, PLA, ARMY, 1 North Street, Yangfang Town, Changping District, Beijing 102205, China
| | - Jingfei Chen
- Institute of NBC Defence, PLA, ARMY, 1 North Street, Yangfang Town, Changping District, Beijing 102205, China
- Unit No. 32169 of PLA, 100 Shuangyong East Road, Nyingchi, Tibet 860000, China
| |
Collapse
|
3
|
Sun X, Song L, Lin L, Ding A, Wang C, Ma X, Zhou S, Cai J, Tang H. Development of tenofovir monobenzyl ester phosphonoamidate prodrugs with improved anti-hepatitis B virus activity and intrahepatic tenofovir enrichment. Bioorg Med Chem 2024; 99:117607. [PMID: 38246114 DOI: 10.1016/j.bmc.2024.117607] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2023] [Revised: 01/11/2024] [Accepted: 01/16/2024] [Indexed: 01/23/2024]
Abstract
Various tenofovir (TFV) prodrugs have been developed by introducing masking groups to the hydroxyls of the monophosphonate group to enhance intestinal absorption efficiency and therapeutic effects. However, the reported TFV prodrugs have drawbacks such as low bioavailability, systemic toxicity caused by their breakdown in non-targeted tissues, and potential low intracellular conversion efficiency. In the present study, we developed a class of TFV monobenzyl ester phosphonoamidate prodrugs without substitutions on the benzene ring. Compared with previous TFV prodrugs, compounds 3a and 3b developed in the present study showed higher anti-hepatitis B virus activity, stronger stability and higher levels of intrahepatic enrichment of the metabolic product (TFV), indicating the potential of these compounds as novel prodrugs with high efficiency and low systemic toxicity for the treatment of hepatitis B.
Collapse
Affiliation(s)
- Xizheng Sun
- Jiangsu Tasly Diyi Pharmaceutical Co., Ltd., Huaian 223003, Jiangsu, China; School of Medicine, Nankai University, Tianjin 300071, China
| | - Li Song
- Jiangsu Tasly Diyi Pharmaceutical Co., Ltd., Huaian 223003, Jiangsu, China
| | - Ling Lin
- Jiangsu Tasly Diyi Pharmaceutical Co., Ltd., Huaian 223003, Jiangsu, China
| | - Aizhong Ding
- Jiangsu Tasly Diyi Pharmaceutical Co., Ltd., Huaian 223003, Jiangsu, China
| | - Chunjian Wang
- Jiangsu Tasly Diyi Pharmaceutical Co., Ltd., Huaian 223003, Jiangsu, China
| | - Xiaohui Ma
- Tasly Academy, Tasly Pharmaceutical Group Co., Ltd., Tianjin 300410, China
| | - Shuiping Zhou
- Tasly Academy, Tasly Pharmaceutical Group Co., Ltd., Tianjin 300410, China
| | - Jinyong Cai
- Jiangsu Tasly Diyi Pharmaceutical Co., Ltd., Huaian 223003, Jiangsu, China
| | - Hai Tang
- Jiangsu Tasly Diyi Pharmaceutical Co., Ltd., Huaian 223003, Jiangsu, China.
| |
Collapse
|
4
|
Roy B, Navarro V, Peyrottes S. Prodrugs of Nucleoside 5'-Monophosphate Analogues: Overview of the Recent Literature Concerning their Synthesis and Applications. Curr Med Chem 2023; 30:1256-1303. [PMID: 36093825 DOI: 10.2174/0929867329666220909122820] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2022] [Revised: 07/21/2022] [Accepted: 08/02/2022] [Indexed: 11/22/2022]
Abstract
Nucleoside analogues are widely used as anti-infectious and antitumoral agents. However, their clinical use may face limitations associated with their physicochemical properties, pharmacokinetic parameters, and/or their peculiar mechanisms of action. Indeed, once inside the cells, nucleoside analogues require to be metabolized into their corresponding (poly-)phosphorylated derivatives, mediated by cellular and/or viral kinases, in order to interfere with nucleic acid biosynthesis. Within this activation process, the first-phosphorylation step is often the limiting one and to overcome this limitation, numerous prodrug approaches have been proposed. Herein, we will focus on recent literature data (from 2015 and onwards) related to new prodrug strategies, the development of original synthetic approaches and novel applications of nucleotide prodrugs (namely pronucleotides) leading to the intracellular delivery of 5'-monophosphate nucleoside analogues.
Collapse
Affiliation(s)
- Béatrice Roy
- Team Nucleosides & Phosphorylated Effectors, Institute for Biomolecules Max Mousseron (IBMM), University of Montpellier, Route de Mende, 34293 Montpellier, France
| | - Valentin Navarro
- Team Nucleosides & Phosphorylated Effectors, Institute for Biomolecules Max Mousseron (IBMM), University of Montpellier, Route de Mende, 34293 Montpellier, France
| | - Suzanne Peyrottes
- Team Nucleosides & Phosphorylated Effectors, Institute for Biomolecules Max Mousseron (IBMM), University of Montpellier, Route de Mende, 34293 Montpellier, France
| |
Collapse
|
5
|
Lv JX, Ding YQ, Huang CM, Guo LL, Fang JL, Jia X, Zhang WH, You S, Qin B. Enzyme- and Chemo-enzyme-Catalyzed Stereodivergent Synthesis. PHARMACEUTICAL FRONTS 2022. [DOI: 10.1055/s-0042-1755556] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022] Open
Abstract
Multiple stereoisomers can be found when a substance contains chiral carbons in its chemical structure. To obtain the desired stereoisomers, asymmetric synthesis was proposed in the 1970s and developed rapidly at the beginning of this century. Stereodivergent synthesis, an extension of asymmetric synthesis in organic synthesis with the hope to produce all stereoisomers of chiral substances in high conversion and selectivity, enriches the variety of available products and serves as a reference suggestion for the synthesis of their derivatives and other compounds. Since biocatalysis has outstanding advantages of economy, environmental friendliness, high efficiency, and reaction at mild conditions, the biocatalytic reaction is regarded as an efficient strategy to perform stereodivergent synthesis. Thus, in this review, we summarize the stereodivergent synthesis catalyzed by enzymes or chemo-enzymes in cases where a compound contains two or three chiral carbons, i.e., at most four or eight stereoisomers are present. The types of reactions, including reduction of substituent ketones, cyclization reactions, olefin addition, and nonredox transesterification reactions, are also discussed for the understanding of the progress and application of biocatalysis in stereodivergent synthesis.
Collapse
Affiliation(s)
- Jia-Xiang Lv
- Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, People's Republic of China
| | - Ya-Qi Ding
- Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, People's Republic of China
| | - Chen-Ming Huang
- Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, People's Republic of China
| | - Ling-Ling Guo
- Microbial Research Institute of Liaoning Province, Liaoyang, People's Republic of China
| | - Jia-Li Fang
- Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, People's Republic of China
| | - Xian Jia
- School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, People's Republic of China
| | - Wen-He Zhang
- School of Life Sciences and Biopharmaceutical Sciences, Shenyang Pharmaceutical University, Shenyang, People's Republic of China
| | - Song You
- School of Life Sciences and Biopharmaceutical Sciences, Shenyang Pharmaceutical University, Shenyang, People's Republic of China
| | - Bin Qin
- Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, People's Republic of China
| |
Collapse
|
6
|
Cosgrove SC, Miller GJ. Advances in biocatalytic and chemoenzymatic synthesis of nucleoside analogues. Expert Opin Drug Discov 2022; 17:355-364. [PMID: 35133222 DOI: 10.1080/17460441.2022.2039620] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
INTRODUCTION Nucleoside analogues represent a cornerstone of achievement in drug discovery, rising to prominence particularly in the fields of antiviral and anticancer discovery over the last 60 years. Traditionally accessed using chemical synthesis, a paradigm shift to include the use of biocatalytic synthesis is now apparent. AREAS COVERED Herein, the authors discuss the recent advances using this technology to access nucleoside analogues. Two key aspects are covered, the first surrounding methodology concepts, effectively using enzymes to access diverse nucleoside analogue space and also for producing key building blocks. The second focuses on the use of biocatalytic cascades for de novo syntheses of nucleoside analogue drugs. Finally, recent advances in technologies for effecting enzymatic nucleoside synthesis are considered, chiefly immobilization and flow. EXPERT OPINION Enzymatic synthesis of nucleoside analogues is maturing but has yet to usurp chemical synthesis as a first-hand synthesis technology, with scalability and substrate modification primary issues. Moving forward, tandem approaches that harness expertise across molecular microbiology and chemical synthesis will be vital to unlocking the potential of next generation nucleoside analogue drug discovery.
Collapse
Affiliation(s)
- Sebastian C Cosgrove
- Lennard-Jones Laboratory, School of Chemical and Physical Sciences, Keele University, Keele, Staffordshire, UK.,Centre for Glycoscience Research, Keele University, Keele, Staffordshire, UK
| | - Gavin J Miller
- Lennard-Jones Laboratory, School of Chemical and Physical Sciences, Keele University, Keele, Staffordshire, UK.,Centre for Glycoscience Research, Keele University, Keele, Staffordshire, UK
| |
Collapse
|
7
|
Franco-Pérez M, Castrejón-Flores JL, González-González S, Landa IB, Zamudio-Medina A. A new tricomponent reaction for the synthesis of symmetric and asymmetric alkyl bisphosphoramidates. PHOSPHORUS SULFUR 2021. [DOI: 10.1080/10426507.2021.1946061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- Marco Franco-Pérez
- Departamento de Física y Química Teórica, Facultad de Química, Universidad Nacional Autónoma de México, CDMX, Mexico
| | | | | | - Israel Bonilla Landa
- Red de Estudios Moleculares Avanzados CAMPUS III, Instituto de Ecología A.C. (INECOL), Xalapa-Enríquez, Mexico
| | - Angel Zamudio-Medina
- Instituto Politécnico Nacional, Unidad Profesional Interdisciplinaria de Biotecnología, CDMX, Mexico
| |
Collapse
|
8
|
Zamudio-Medina A, Pérez-Hernández N, Castrejón-Flores JL, Romero-García S, Prado-García H, Bañuelos-Hernández A, Franco-Pérez M. Obtaining symmetric and asymmetric bisphosphoramidates and bisphosphoramidothioates by a single step multicomponent reaction. PHOSPHORUS SULFUR 2021. [DOI: 10.1080/10426507.2021.1878358] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Affiliation(s)
- Angel Zamudio-Medina
- Unidad Profesional Interdisciplinaria de Biotecnología, Instituto Politécnico Nacional, CDMX, México
| | - Nury Pérez-Hernández
- Escuela Nacional de Medicina y Homeopatía, Instituto Politécnico Nacional, CDMX, México
| | | | - Susana Romero-García
- Department of Chronic-Degenerative Diseases, National Institute of Respiratory Diseases “Ismael Cosío Villegas”, Mexico City, Mexico
| | - Heriberto Prado-García
- Department of Chronic-Degenerative Diseases, National Institute of Respiratory Diseases “Ismael Cosío Villegas”, Mexico City, Mexico
| | | | - Marco Franco-Pérez
- Departamento de Física y Química Teórica, Facultad de Química, Universidad Nacional Autónoma de México, Ciudad Universitaria, CDMX, México
| |
Collapse
|
9
|
Ambrosi A, Bringley DA, Calimsiz S, Garber JAO, Huynh H, Mohan S, Sarma K, Shen J, Curl J, Kwong B, Lapina O, Leung E, Lin L, Martins A, McGinitie T, Phull J, Roberts B, Rosario M, Shi B, Standley EA, Wang L, Wang X, Yu G. Synthesis of Rovafovir Etalafenamide (Part III): Evolution of the Synthetic Process to the Phosphonamidate Fragment. Org Process Res Dev 2021. [DOI: 10.1021/acs.oprd.0c00428] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Affiliation(s)
- Andrea Ambrosi
- Process Chemistry, Gilead Sciences Inc., 333 Lakeside Drive, Foster City, California 94404, United States
| | - Dustin A. Bringley
- Process Chemistry, Gilead Sciences Inc., 333 Lakeside Drive, Foster City, California 94404, United States
| | - Selcuk Calimsiz
- Process Development, Gilead Alberta ULC, 1021 Hayter Road NW, Edmonton, Alberta T6S 1A1, Canada
| | - Jeffrey A. O. Garber
- Process Development, Gilead Alberta ULC, 1021 Hayter Road NW, Edmonton, Alberta T6S 1A1, Canada
| | - Huy Huynh
- Process Development, Gilead Alberta ULC, 1021 Hayter Road NW, Edmonton, Alberta T6S 1A1, Canada
| | - Sankar Mohan
- Process Development, Gilead Alberta ULC, 1021 Hayter Road NW, Edmonton, Alberta T6S 1A1, Canada
| | - Keshab Sarma
- Process Chemistry, Gilead Sciences Inc., 333 Lakeside Drive, Foster City, California 94404, United States
| | - Jinyu Shen
- Process Development, Gilead Alberta ULC, 1021 Hayter Road NW, Edmonton, Alberta T6S 1A1, Canada
| | - Jonah Curl
- Process Development, Gilead Alberta ULC, 1021 Hayter Road NW, Edmonton, Alberta T6S 1A1, Canada
| | - Bernard Kwong
- Process Development, Gilead Alberta ULC, 1021 Hayter Road NW, Edmonton, Alberta T6S 1A1, Canada
| | - Olga Lapina
- Process Chemistry, Gilead Sciences Inc., 333 Lakeside Drive, Foster City, California 94404, United States
| | - Edmund Leung
- Process Development, Gilead Alberta ULC, 1021 Hayter Road NW, Edmonton, Alberta T6S 1A1, Canada
| | - Lennie Lin
- Process Development, Gilead Alberta ULC, 1021 Hayter Road NW, Edmonton, Alberta T6S 1A1, Canada
| | - Andrew Martins
- Process Development, Gilead Alberta ULC, 1021 Hayter Road NW, Edmonton, Alberta T6S 1A1, Canada
| | - Teague McGinitie
- Analytical Chemistry, Gilead Alberta ULC, 1021 Hayter Road NW, Edmonton, Alberta T6S 1A1, Canada
| | - Jaspal Phull
- Process Development, Gilead Alberta ULC, 1021 Hayter Road NW, Edmonton, Alberta T6S 1A1, Canada
| | - Ben Roberts
- Process Chemistry, Gilead Sciences Inc., 333 Lakeside Drive, Foster City, California 94404, United States
| | - Mary Rosario
- Process Development, Gilead Alberta ULC, 1021 Hayter Road NW, Edmonton, Alberta T6S 1A1, Canada
| | - Bing Shi
- Process Chemistry, Gilead Sciences Inc., 333 Lakeside Drive, Foster City, California 94404, United States
| | - Eric A. Standley
- Process Chemistry, Gilead Sciences Inc., 333 Lakeside Drive, Foster City, California 94404, United States
| | - Li Wang
- Process Development, Gilead Alberta ULC, 1021 Hayter Road NW, Edmonton, Alberta T6S 1A1, Canada
| | - Xueqing Wang
- Process Development, Gilead Alberta ULC, 1021 Hayter Road NW, Edmonton, Alberta T6S 1A1, Canada
| | - Guojun Yu
- Process Development, Gilead Alberta ULC, 1021 Hayter Road NW, Edmonton, Alberta T6S 1A1, Canada
| |
Collapse
|
10
|
Wang L, Sun Y. Engineering organophosphate hydrolase for enhanced biocatalytic performance: A review. Biochem Eng J 2021. [DOI: 10.1016/j.bej.2021.107945] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
|
11
|
Slagman S, Fessner WD. Biocatalytic routes to anti-viral agents and their synthetic intermediates. Chem Soc Rev 2021; 50:1968-2009. [DOI: 10.1039/d0cs00763c] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
An assessment of biocatalytic strategies for the synthesis of anti-viral agents, offering guidelines for the development of sustainable production methods for a future COVID-19 remedy.
Collapse
Affiliation(s)
- Sjoerd Slagman
- Institut für Organische Chemie und Biochemie
- Technische Universität Darmstadt
- Germany
| | - Wolf-Dieter Fessner
- Institut für Organische Chemie und Biochemie
- Technische Universität Darmstadt
- Germany
| |
Collapse
|
12
|
Wohlgemuth R. Key advances in biocatalytic phosphorylations in the last two decades: Biocatalytic syntheses in vitro and biotransformations in vivo (in humans). Biotechnol J 2020; 16:e2000090. [PMID: 33283467 DOI: 10.1002/biot.202000090] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2020] [Revised: 11/06/2020] [Indexed: 01/05/2023]
Abstract
Biocatalytic phosphorylation reactions provide several benefits, such as more direct, milder, more selective, and shorter access routes to phosphorylated products. Favorable characteristics of biocatalytic methodologies represent advantages for in vitro as well as for in vivo phosphorylation reactions, leading to important advances in the science of synthesis towards bioactive phosphorylated compounds in various areas. The scope of this review covers key advances of biocatalytic phosphorylation reactions over the last two decades, for biocatalytic syntheses in vitro and for biotransformations in vivo (in humans). From the origins of probiotic life to in vitro synthetic applications and in vivo formation of bioactive pharmaceuticals, the common purpose is to outline the importance, relevance, and underlying connections of biocatalytic phosphorylations of small molecules. Asymmetric phosphorylations attracting increased attention are highlighted. Phosphohydrolases, phosphotransferases, phosphorylases, phosphomutases, and other enzymes involved in phosphorus chemistry provide powerful toolboxes for resource-efficient and selective in vitro biocatalytic syntheses of phosphorylated metabolites, chiral building blocks, pharmaceuticals as well as in vivo enzymatic formation of biologically active forms of pharmaceuticals. Nature's large diversity of phosphoryl-group-transferring enzymes, advanced enzyme and reaction engineering toolboxes make biocatalytic asymmetric phosphorylations using enzymes a powerful and privileged phosphorylation methodology.
Collapse
Affiliation(s)
- Roland Wohlgemuth
- Institute of Molecular and Industrial Biotechnology, Lodz University of Technology, Lodz, Poland.,Swiss Coordination Committee Biotechnology, Zurich, Switzerland
| |
Collapse
|
13
|
Bigley AN, Narindoshvili T, Raushel FM. A Chemoenzymatic Synthesis of the ( RP)-Isomer of the Antiviral Prodrug Remdesivir. Biochemistry 2020; 59:3038-3043. [PMID: 32786401 PMCID: PMC7418565 DOI: 10.1021/acs.biochem.0c00591] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2020] [Revised: 08/04/2020] [Indexed: 12/16/2022]
Abstract
The COVID-19 pandemic threatens to overwhelm healthcare systems around the world. The only current FDA-approved treatment, which directly targets the virus, is the ProTide prodrug remdesivir. In its activated form, remdesivir prevents viral replication by inhibiting the essential RNA-dependent RNA polymerase. Like other ProTide prodrugs, remdesivir contains a chiral phosphorus center. The initial selection of the (SP)-diastereomer for remdesivir was reportedly due to the difficulty in producing the pure (RP)-diastereomer of the required precursor. However, the two currently known enzymes responsible for the initial activation step of remdesivir are each stereoselective and show differential tissue distribution. Given the ability of the COVID-19 virus to infect a wide array of tissue types, inclusion of the (RP)-diastereomer may be of clinical significance. To help overcome the challenge of obtaining the pure (RP)-diastereomer of remdesivir, we have developed a novel chemoenzymatic strategy that utilizes a stereoselective variant of the phosphotriesterase from Pseudomonas diminuta to enable the facile isolation of the pure (RP)-diastereomer of the chiral precursor for the chemical synthesis of the (RP)-diastereomer of remdesivir.
Collapse
Affiliation(s)
- Andrew N. Bigley
- Department of Chemistry, Texas A&M University, College Station, Texas 77843, United States
| | - Tamari Narindoshvili
- Department of Chemistry, Texas A&M University, College Station, Texas 77843, United States
| | - Frank M. Raushel
- Department of Chemistry, Texas A&M University, College Station, Texas 77843, United States
| |
Collapse
|
14
|
Sagaama A, Brandan SA, Ben Issa T, Issaoui N. Searching potential antiviral candidates for the treatment of the 2019 novel coronavirus based on DFT calculations and molecular docking. Heliyon 2020; 6:e04640. [PMID: 32802981 PMCID: PMC7409764 DOI: 10.1016/j.heliyon.2020.e04640] [Citation(s) in RCA: 43] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2020] [Revised: 06/15/2020] [Accepted: 08/03/2020] [Indexed: 01/18/2023] Open
Abstract
In the present work, the succinic acid (SA), L-pyroglutamic acid (L-PGA), N-phenyl-thioacetamide (N-NPTA), 2-amino-5-chloropyridine hydrogen succinate (ACPS), epigallocatechine Gallate (EGCG) or KDH and, selenomethionine (SeM) compounds have been proposed as potential antiviral candidates to treatment of COVID-19 based on B3LYP/6-311++G∗∗ calculations and molecular docking. Solvation energies, stabilization energies, topological properties have been evaluated as function of acceptors and donors groups present in their structures. ACPS presents the higher reactivity in solution possibly because has the higher nucleophilicity and elecrophilicity indexes while KDH evidence the higher solvation energy probably due to the higher quantity of donors and acceptors groups. NBO studies show that KDH is the most stable in solution. Mapped MEP surfaces have evidenced stronger nucleophilic and electrophilic sites in ACPS, in agreement with the three C=O and two N-H and O-H groups present in this species while KDH has only a C=O group but a total of 19 acceptors and donors groups. From the above studies for six species we can propose that the better potential antiviral candidate to treatment of COVID-19 is ACPS and then, KDH. For a better prediction of the antiviral and anti-inflammatory properties of the proposed compounds, molecular docking calculations were performed by using four structures of COVID-19. Docking results were discussed basing on binding affinities and the interaction types among ligands and different amino acid residues, indicating the powerful ability of KDH and then ACPS ligands on front of the novel coronavirus disease especially for the first and the fourth species (6LU7, 7BTF).
Collapse
Affiliation(s)
- Abir Sagaama
- University of Monastir, Laboratory of Quantum and Statistical Physics (LR18ES18), Faculty of Sciences, Monastir 5079, Tunisia
| | - Silvia Antonia Brandan
- Cátedra de Química General, Instituto de Química Inorgánica, Facultad de Bioquímica, Química y Farmacia, Universidad Nacional de Tucumán, Ayacucho 471, 4000, San Miguel de Tucumán, Tucumán, Argentina
| | - Takoua Ben Issa
- University of Monastir, Laboratory of Quantum and Statistical Physics (LR18ES18), Faculty of Sciences, Monastir 5079, Tunisia
| | - Noureddine Issaoui
- University of Monastir, Laboratory of Quantum and Statistical Physics (LR18ES18), Faculty of Sciences, Monastir 5079, Tunisia
| |
Collapse
|